Table 2

Structural joint damage in patients randomised to CZP treatment at Week 0

(A) Change in mTSS from baseline to Week 216
Week 0 CZP dose combined (n=273)
mTSS at baseline
Observed case (n=269)
 Mean (SD)16.03 (34.67)
 Median4.50
 (Min, max)(0, 342.5)
MMRM estimates, least squares (LS) mean (SE), 95% CI
mTSS at baseline15.96 (2.24), 11.55 to 20.36
 CFB at Week 960.28 (0.12), 0.04 to 0.51
 CFB at Week 1680.62 (0.19), 0.25 to 0.99
 CFB at Week 2160.72 (0.20), 0.33 to 1.11